Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.41 |
| ▸ | MEN1 | O00255 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2898995 | 0.92 | MERTK (0.59) | MERTKKMT2AMEN1MAPTPOLB | |
| SCHEMBL2896050 | 0.91 | MERTK (0.58) | MERTKKMT2AMEN1MAPTPOLB | |
| SCHEMBL2902504 | 0.89 | MERTK (0.56) | MERTKKMT2AMEN1MAPTPOLB | |
| SCHEMBL2904566 | 0.88 | MAPK1 (0.48) | MERTKKMT2AMEN1MAPTPOLB | |
| SCHEMBL16969423 | 0.85 | MERTK (0.51) | MERTKKMT2AMEN1MAPTPOLB | |
| SCHEMBL2902625 | 0.85 | MERTK (0.52) | MERTKKMT2AMEN1MAPTPOLB | |
| SCHEMBL2896915 | 0.83 | MERTK (0.47) | MERTKKMT2AMEN1MAPTPOLB | |
| SCHEMBL3750731 | 0.81 | MERTK (0.45) | MERTKKMT2AMEN1MAPTPOLB | |
| SCHEMBL16969474 | 0.81 | MERTK (0.53) | MERTKKMT2AMEN1MAPTPOLB | |
| SCHEMBL16969534 | 0.81 | MERTK (0.50) | MERTKKMT2AMEN1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2213650-B1 | SUBSTITUTED DIPHENYLAMINES AS INHIBITORS OF REVERSE TRANSCRIPTASE, PROCESS OF PREPARING THEM AND USE THEREOF | INST PHARM & TOXICOLOGY AMMS (CN) | 2015-08-12 | — | — | EP | claimed |
| US-8309602-B2 | Multi-substituted diarylanilines as non-nucleoside HIV reverse transcriptase inhibitors, and preparation and use thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY (CN) | 2012-11-13 | — | — | US | claimed |
| US-20100292324-A1 | Multi-Substituted Diarylanilines as Non-Nucleoside HIV Reverse Transcriptase Inhibitors, and Preparation and Use Thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2010-11-18 | — | — | US | claimed |
| EP-2213650-A1 | SUBSTITUTED DIPHENYLAMINES AS INHIBITORS OF REVERSE TRANSCRIPTASE, PROCESS OF PREPARING THEM AND USE THEREOF | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China (CN) | 2010-08-04 | — | — | EP | claimed |
| EP-2213650-B1 | SUBSTITUTED DIPHENYLAMINES AS INHIBITORS OF REVERSE TRANSCRIPTASE, PROCESS OF PREPARING THEM AND USE THEREOF | INST PHARM & TOXICOLOGY AMMS (CN) | 2015-08-12 | — | — | EP | disclosed |
| US-8309602-B2 | Multi-substituted diarylanilines as non-nucleoside HIV reverse transcriptase inhibitors, and preparation and use thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY (CN) | 2012-11-13 | — | — | US | disclosed |
| US-20100292324-A1 | Multi-Substituted Diarylanilines as Non-Nucleoside HIV Reverse Transcriptase Inhibitors, and Preparation and Use Thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2010-11-18 | — | — | US | disclosed |
| EP-2213650-A1 | SUBSTITUTED DIPHENYLAMINES AS INHIBITORS OF REVERSE TRANSCRIPTASE, PROCESS OF PREPARING THEM AND USE THEREOF | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China (CN) | 2010-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292324-A1 | Multi-Substituted Diarylanilines as Non-Nucleoside HIV Reverse Transcriptase Inhibitors, and Preparation and Use Thereof | PNP, POLRMT, QTRT1 | MERTK 3429/4885KMT2A 418/4885MEN1 3688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.